Myocardial tissue characterisation in left ventricular hypertrophy using echocardiography and cardiac magnetic resonance.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000156987

Enrollment

Registered

2011-02-09

Start date

2011-02-28

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This research project composes of collecting echocardiographic and cardiac MRI (CMR) data on two populations of patients; those with severe aortic stenosis and those with systemic hypertension and comparing them to healthy subjects. We would like to use the data collected on these two cohorts of patients to look at 2 dimensional strain imaging, tissue Doppler imaging, three dimensional volumes and myocardial fibrosis. By using these advanced imaging techniques we can evaluate and quantify left ventricular (LV) hypertrophy and myocardial characteristics. This may give us a better understanding of cardiac remodelling and the function of the heart muscle in each of these disease states. We hypothesise that differences in myocardial function and tissue characterisation detected by these imaging techniques may be detected in patients aortic stenosis and hypertension with similar degrees of LV hypertrophy.

Interventions

Echocardiogram will be performed to measure strain and diastolic cardiac function. Cardiac Magnetic Resonance Imaging will be performed to measure myocardial fibrosis and perfusion reserve . These tests will take approximately 90 minutes, and will performed once only in each patient, from either the aortic stenosis cohort, the systemic hypertension cohort or the healthy subjects.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Cohort 1. Patients with history of aortic stenosis. Cohort 2. patients with history of systemic hypertension Cohort 3. healthy subjects, no history of AS or hypertension

Exclusion criteria

Known cardiovascular disease Known peripheral vascular disease Hypercholesterolemia (total cholesterol > 6mmol/L) Diabetes (type I or II) Metabolic syndrome and a BMI of < 30 Standard MRI contraindications, including permanent pacemaker, implantable defibrillator, severe claustrophobia. Renal impairment (eGFR < 60ml/min) will be an exclusion criterion from the administration of gadolinium

Outcome results